Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.
Open Access
- 1 December 1993
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 178 (6) , 2123-2130
- https://doi.org/10.1084/jem.178.6.2123
Abstract
Allergen specific CD4+ T cell clones generated from allergic individuals have been shown to produce increased levels of the cytokine interleukin 4 (IL-4), compared to allergen specific clones generated from nonallergic individuals. This difference between CD4+ T cells from allergic and nonallergic individuals with regard to cytokine production in response to allergen is thought to be responsible for the development of allergic disease with increased IgE synthesis in atopic individuals. We examined the production of IL-4 in subjects with allergic rhinitis and in allergic individuals treated with allergen immunotherapy, a treatment which involves the subcutaneous administration of increasing doses of allergen and which is highly effective and beneficial for individuals with severe allergic rhinitis. We demonstrated that the quantity of IL-4 produced by allergen specific memory CD4+ T cells from allergic individuals could be considerably reduced by in vivo treatment with allergen (allergen immunotherapy). Immunotherapy reduced IL-4 production by allergen specific CD4+ T cells to levels observed with T cells from nonallergic subjects, or to levels induced with nonallergic antigens such as tetanus toxoid. In most cases the levels of IL-4 produced were inversely related to the length of time on immunotherapy. These observations indicate that immunotherapy accomplishes its clinical effects by reducing IL-4 synthesis in allergen specific CD4+ T cells. In addition, these observations indicate that the cytokine profiles of memory CD4+ T cells can indeed be altered by in vivo therapies. Thus, the cytokine profiles of memory CD4+ T cells are mutable, and are not fixed as had been suggested by studies of murine CD4+ memory T cells. Finally, treatment of allergic diseases with allergen immunotherapy may be a model for other diseases which may require therapies that alter inappropriate cytokine profiles of memory CD4+ T cells.Keywords
This publication has 36 references indexed in Scilit:
- Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced MacrophagesScience, 1993
- Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.The Journal of Experimental Medicine, 1993
- Development and transfer of immediate cutaneous hypersensitivity in mice exposed to aerosolized antigen.Journal of Clinical Investigation, 1993
- Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic AsthmaNew England Journal of Medicine, 1992
- Functional subsets of allergen-reactive human CD4+ T cellsImmunology Today, 1991
- Differing Lymphokine Profiles of Functional Subsets of Human CD4 and CD8 T Cell ClonesScience, 1991
- Immunotherapy for nasal allergyJournal of Allergy and Clinical Immunology, 1988
- A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay feverJournal of Allergy and Clinical Immunology, 1982
- Generation of Antigen-Specific Suppressor Cells during Allergy DesensitizationNew England Journal of Medicine, 1980
- The effect of immunotherapy on humoral and cellular responses in ragweed hayfever.Journal of Clinical Investigation, 1976